Skip to navigation

Glesatinib (MGCD265)

Indications: Non-Small Cell Lung Cancer
Drug Candidate: Glesatinib (MGCD265)
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of Glesatinib (MGCD265) as a treatment for Non-Small Cell Lung Cancer patients whose tumors carry genetic alterations of MET and Axl. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if selected mutations are present before enrolling in the clinical trial.

Find an Active Trial

Related Resources

Non-Small Cell Lung Cancer